1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1517/13543776.2014.931375" target="_blank" rel="noreferrer noopener">http://doi.org/10.1517/13543776.2014.931375</a>
Pages
947–951
Issue
8
Volume
24
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Parkinson's disease biomarker: a patent evaluation of WO2013153386.
Publisher
An entity responsible for making the resource available
Expert opinion on therapeutic patents
Date
A point or period of time associated with an event in the lifecycle of the resource
2014
2014-08
Subject
The topic of the resource
Humans; Disease Progression; Biomarkers/metabolism; Phosphorylation; Mitochondria/pathology; mitophagy; autophagy; clinical testing; Dopaminergic Neurons/pathology; mitochondrial membrane potential; Parkinson Disease/*diagnosis/physiopathology; Patents as Topic; Protein Kinases/*metabolism; Ubiquitin-Protein Ligases/*metabolism
Creator
An entity primarily responsible for making the resource
Geldenhuys Werner J; Abdelmagid Samir M; Gallegos Patrick J; Safadi Fayez F
Description
An account of the resource
INTRODUCTION: Parkinson's disease (PD) is a neurodegenerative movement disorder resultant from the loss of dopaminergic neurons in the brain. There is an urgent need for effective biomarkers that can be used in the early diagnosis of PD. Mitochondrial dysfunction plays a significant role in PD pathology, which has led to the evaluation of mitophagy markers, PTEN-induced putative kinase 1 (PINK1), and PARKIN as possible biomarkers for the early diagnosis of PD. AREAS COVERED: The current patent describes the use of phosphorylation of PINK1 and PARKIN as a diagnostic measure. Specifically, Ser65 on PARKIN, which is phosphorylated by PINK1, and the autophosphorylation of PINK1 at Thr257 are described. EXPERT OPINION: This patent describes a much needed methodology that can easily be adapted in the clinical setting by which a biological sample, such as serum or cerebrospinal fluid, is collected and analyzed for the phosphorylation markers. Here, the phosphorylation activity seen in PINK1 and PARKIN can differentiate between age-matched controls and PD patients. This patent presents a novel diagnostic measure in early PD, as well as determines which medications would have a beneficial effect on a patient's disease progression.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1517/13543776.2014.931375" target="_blank" rel="noreferrer noopener">10.1517/13543776.2014.931375</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2014
Abdelmagid Samir M
Autophagy
Biomarkers/metabolism
clinical testing
Department of Anatomy & Neurobiology
Department of Pharmaceutical Sciences
Department of Pharmacy Practice
Disease Progression
Dopaminergic Neurons/pathology
Expert opinion on therapeutic patents
Gallegos Patrick J
Geldenhuys Werner J
Humans
Mitochondria/pathology
mitochondrial membrane potential
mitophagy
NEOMED College of Medicine
NEOMED College of Pharmacy
Parkinson Disease/*diagnosis/physiopathology
Patents as Topic
Phosphorylation
Protein Kinases/*metabolism
Safadi Fayez F
Ubiquitin-Protein Ligases/*metabolism